BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 36364046)

  • 1. [
    Maurin M; Wyczółkowska M; Sawicka A; Sikora AE; Karczmarczyk U; Janota B; Radzik M; Kłudkiewicz D; Pijarowska-Kruszyna J; Jaroń A; Wojdowska W; Garnuszek P
    Molecules; 2022 Oct; 27(21):. PubMed ID: 36364046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical translation of a PSMA inhibitor for
    Ferro-Flores G; Luna-Gutiérrez M; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Orocio-Rodríguez E; Davanzo J; García-Pérez FO
    Nucl Med Biol; 2017 May; 48():36-44. PubMed ID: 28193503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
    Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
    J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen.
    Mosayebnia M; Hajimahdi Z; Beiki D; Rezaeianpour M; Hajiramezanali M; Geramifar P; Sabzevari O; Amini M; Hatamabadi D; Shahhosseini S
    Bioorg Chem; 2020 Jun; 99():103743. PubMed ID: 32217372
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Xu X; Zhang J; Hu S; He S; Bao X; Ma G; Luo J; Cheng J; Zhang Y
    Nucl Med Biol; 2017 May; 48():69-75. PubMed ID: 28273495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Evaluation of
    Lu K; Zhang C; Zhang Z; Kuo HT; Colpo N; Bénard F; Lin KS
    Molecules; 2023 Jun; 28(13):. PubMed ID: 37446782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetry estimation and preliminary clinical application of [
    Yang H; Gao Z; Xu X; Liu C; Hu S; Zhang J; Song S
    Ann Nucl Med; 2023 Jan; 37(1):60-69. PubMed ID: 36346503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Radiation dosimetry of
    Zhang J; Zhang J; Xu X; Lu L; Hu S; Liu C; Cheng J; Song S; Zhang Y; Shi LQ
    Sci Rep; 2020 Mar; 10(1):4179. PubMed ID: 32144340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.
    Vallabhajosula S; Nikolopoulou A; Babich JW; Osborne JR; Tagawa ST; Lipai I; Solnes L; Maresca KP; Armor T; Joyal JL; Crummet R; Stubbs JB; Goldsmith SJ
    J Nucl Med; 2014 Nov; 55(11):1791-8. PubMed ID: 25342385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and Biological Evaluation of [
    Xiao D; Duan X; Gan Q; Zhang X; Zhang J
    Molecules; 2020 Nov; 25(23):. PubMed ID: 33256058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
    Lawal IO; Ankrah AO; Mokgoro NP; Vorster M; Maes A; Sathekge MM
    Prostate; 2017 Aug; 77(11):1205-1212. PubMed ID: 28649735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [
    Mamlins E; Scharbert L; Cardinale J; Krotov M; Winter E; Rathke H; Strodel B; Ankrah AO; Sathekge M; Haberkorn U; Kratochwil C; Giesel FL
    Mol Imaging Biol; 2024 Feb; 26(1):81-89. PubMed ID: 38066252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of hybrid
    Janssen JC; Meißner S; Woythal N; Prasad V; Brenner W; Diederichs G; Hamm B; Makowski MR
    Eur Radiol; 2018 Feb; 28(2):610-619. PubMed ID: 28779400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Characterization of
    Bolzati C; Gobbi C; Ferro-Flores G; Turato S; Ocampo-Garcia B; Carpanese D; Marzano C; Spolaore B; Fracasso G; Rosato A; Meléndez-Alafort L
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Evaluation of a Novel High-Affinity Radioligand [
    Bezverkhniaia E; Kanellopoulos P; Abouzayed A; Larkina M; Oroujeni M; Vorobyeva A; Rosenström U; Tolmachev V; Orlova A
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-to-head comparison of
    Zhang Y; Lin Z; Li T; Wei Y; Yu M; Ye L; Cai Y; Yang S; Zhang Y; Shi Y; Chen W
    Sci Rep; 2022 Sep; 12(1):15993. PubMed ID: 36163353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).
    Ray Banerjee S; Pullambhatla M; Foss CA; Falk A; Byun Y; Nimmagadda S; Mease RC; Pomper MG
    J Med Chem; 2013 Aug; 56(15):6108-21. PubMed ID: 23799782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
    J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Yılmaz B; Şahin S; Ergül N; Çolakoğlu Y; Baytekin HF; Sökmen D; Tuğcu V; Taşçı Aİ; Çermik TF
    Ann Nucl Med; 2022 Jul; 36(7):597-609. PubMed ID: 35426599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.